Cardurion Pharmaceuticals has been named one of the Endpoints 11 most promising private biotechnology companies of 2024, recognizing its innovative approach to cardiovascular disease treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.